参考文献/References:
[1] Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. Am J Cardiol, 1974, 34(1):48-55.
[2] Heller LI, Cares C, Popma J, et al. Intracoronary Doppler assessment of moderate coronary artery disease:comparison with 201Tl imaging and coronary angiography. FACTS Study Group. Circulation, 1997, 96(2):484-490.
[3] 朱永胜,张军,George,等.经胸彩色多普勒检测冠心病患者冠状动脉左前降支和右冠状动脉远端血流储备[J].中华心血管病杂志,2005,33(9):801-805.
[4] Nagel E, Thouet T, Klein C, et al. Noninvasive determination of coronary blood flow velocity with cardiovascular magnetic -sonance in patients after stent deployment. Circulation, 2003, 107(13):1738-1743.
[5] Lautamaki R, George RT, Kitagawa K, et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow:validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol hnaging, 2009, 36(4):576-586.
[6] Schindler TH, Zhang XL, Prior JO, et al. Assessment of intra-and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with 13N-ammonia and PET. Eur J Nucl Med Mol Imaging, 2007, 34(8):1178-1188.
[7] Choi Y, Huang SC, Hawkins RA, et al. Quantification of myocardial blood flow using 13N-ammonia and PET:comparison of tracer models. J Nucl Med, 1999, 40(6):1045-55.
[8] Schelbert HR. Quantification of myocardial blood flow:what is the clinical role?. Cardiol Clin, 2009, 27(2):277-289.
[9] Schindler TH, Schelbert HR, Quercioli A, et al. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging, 2010, 3(6):623640.
[10] El Fakhri G, Kardan A, Sitek A, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with 82Rb PET:comparison with 13N-ammonia PET. J Nucl Med, 2009, 50(7):1062-1071.
[11] Nekolla SG, Reder S, Saraste A, et aL Evaluation of the novel myocardial perfusion positron-emission tomography tracer -SF-BMS-747158-02:comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation, 2009, 119(17):2333-2342.
[12] Yu M, Guaraldi MT, Mistry M, et al. BMS-747158-02:a novel PET myocardial perfusion imaging agent. J Nucl Cardiol, 2007, 14(6):789-798.
[13] Mou T, Jing H, Yang W, et al. Preparation and biodistribution of[18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography. Bioorg Med Chem, 201 O, 18(3):1312-1320.
[14] Sato A, Terata K, Miura H, et al. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol, 2005, 288(4):H 1633-1640.
[15] Prior JO, Schindler TH, Facta AD, et al. Determinants cff myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans. Eur J Nucl Med Mol Imaging, 2007, 34(1):20-27.
[16] Schindler TH, Nitzsche EU, Olschewski M, et al. PET-measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. J Nucl Med, 2004, 45(3):419-428.
[17] Kubo S, Tadamura E, Toyoda H, et al. Effect of caffeine intake onmyocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. J Nucl Med, 2004, 45(5):730-738.
[18] Buus NH, Bottcher M, Hermansen F, et al. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation, 2001,104(19):2305-2310.
[19] Kajander SA, Joutsiniemi E, Saraste M, et al. Clinical value of absolute quantification of myocardial perfusion with 15-SO-water in coronary artery disease. Circ Cardiovasc Imaging, 2011, 4(6):678-684.
[20] Gould KL. Quantification of coronary artery stenosis in vivo. Circ Res, 1985, 57(3):341-353.
[21] Uren NG, Melin JA, De Bruyne B, et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med, 1994, 330(25):1782-1788.
[22] Anagnostopoulos C, Almonacid A, El Fakhri G, et al. Quantitative relationship between coronary vasodilator reserve assessed by 82Rb PET imaging and coronary artery stenosis severity. Eur J Nucl Med Mol Imaging, 2008, 35(9):1593-1601.
[23] Parkash R, deKemp RA, Ruddy TD, et al. Potential utility of rubidium-82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol, 2004, 11(4):440-449.
[24] Ziadi MC, Dekemp RA, Williams K, et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of muhivessel coronary artery disease. J Nucl Cardiol, 2012, 19(4):670-80.
[25] Ashikawa K, Kanatsuka H, Suzuki T, et at. Phasic blood flow velocity pattern in epimyoeardial mierovessels in the beating canine left ventricle. Cire Res, 1986, 59(6):704-711.
[26] Jorg-Ciopor M, Namdar M, Turina J, et al. Regional myocardial ischemia in hypertrophic cardiomyopathy:impact of myectomy. J Thorac Cardiovasc Surg, 2004, 128(2):163-169.
[27] Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med, 2003, 349(11):1027-1035.
[28] Canetti M, Akhter MW, Lerman A, et al. Evaluation of myocardial blood flow reserve in patients with chronic congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol, 2003, 92(10):1246-1249.
[29] Stolen KQ, Kemppainen J, Kalliokoski KK, et al. Myocardial perfusion reserve and peripheral endothelial function in patients with idiopathic dilated cardiomyopathy. Am J Cardiol, 2004, 93(1):64-68.
[30] Neglia D, De Maria R, Masi S, et al. Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. Heart, 2007, 93(7):808-813.
[31] Ganz P, Vita JA. Testing endothelial vasomotor function:nitricoxide, a multipotent molecule. Circulation, 2003, 108(17):2049-2053.
[32] Schindler TH, Zhang XL, Vincenti G, et al. Role of PET in the evaluation and understanding of coronary physiology. J Nucl Cardiol, 2007, 14(4):589-603.
[33] Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med, 2009, 50(7):1076-1087.
[34] Prior JO, Quinones M J, Hernandez-Pampaloni M, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation, 2005, 111(18):2291-2298.
[35] Alexanderson E, Jacome R, Jimenez-Santos M, et al. Evaluation of the endothelial function in hypertensive patients with 13N-ammonia PET[J/OL]. J Nucl Cardiol, 201212012-07-09]. http://www.ncbi.nlm.nih.gov/pubmed/22689073.[Epublished online ahead of print June 12, 2012].
[36] Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med, 2009, 50(2):214-219.
[37] Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coil Cardiol, 2009, 54(2):150-156.
[38] Pijls NH, Fearon WF, Toninn PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease:2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Muhivessel Evaluation) study. J Am Coil Cardiol, 2010, 56(3):177-184.
[39] Naya M, Morita K, Yoshinaga K, et al. Long-term smoking causes more advanced coronary endothelial dysfunction in middle-aged smokers compared to young smokers. Eur J Nucl Med Mol Imaging, 2011, 38(3):491-498.
[40] Alexanderson E, Garcia-Rojas L, Jimenez M, et al. Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients:assessment by 13N-ammonia positron emission tomography. J Nucl Cardiol, 2010, 17(6):1015-1022.
[41] Schindler TH, Facta AD, Prior JO, et al. Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. Heart, 2007, 93(3):345-349.
[42] Quinones MJ, Hernandez-Pampaloni M, Schelbert H, et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med, 2004, 140(9):700-708.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]